Updates are available Correction dated 2024-08-02
Click to view Correction: https://doi.org/10.1038/s41523-024-00682-y
-
Authors
Scagnoli, Simone https://orcid.org/0000-0003-4943-5622
Pisegna, Simona https://orcid.org/0000-0002-6910-9528
Toss, Angela
Caputo, Roberta https://orcid.org/0000-0003-4231-1184
De Laurentiis, Michelino https://orcid.org/0000-0001-9009-1572
Palleschi, Michela
de Giorgi, Ugo
Cortesi, Enrico
Fabbri, Agnese
Fabi, Alessandra https://orcid.org/0000-0002-0758-8033
Paris, Ida https://orcid.org/0000-0002-7445-3366
Orlandi, Armando
Curigliano, Giuseppe https://orcid.org/0000-0003-1781-2518
Criscitiello, Carmen
Garrone, Ornella
Tomasello, Gianluca
D’Auria, Giuliana
Vici, Patrizia
Ricevuto, Enrico https://orcid.org/0000-0001-5641-3187
Domati, Federica
Piombino, Claudia https://orcid.org/0000-0002-7224-4536
Parola, Sara
Scafetta, Roberta
Cirillo, Alessio
Taurelli Salimbeni, Beatrice
Di Lisa, Francesca Sofia
Strigari, Lidia https://orcid.org/0000-0003-4293-2298
Preissner, Robert
Simmaco, Maurizio
Santini, Daniele
Marchetti, Paolo
Botticelli, Andrea
- License Information
-
More Information
Article History
Received: 10 June 2023
Accepted: 14 June 2024
First Online: 17 July 2024
Change Date: 2 August 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41523-024-00682-y
Competing interests
: Simone Scagnoli (SS) speaker: novartis, pfizer, roche, lilly, BMS, MSD; Simona Pisegna (SP) speaker for Novartis, Lilly, Pfizer, Roche; Angela Toss (AT) speaker and advisory board Lilly, Novartis, Pfizer, AstraZeneca, MSD; Roberta Caputo (RC) advisory role Roche, Lilly, Novartis, MSD, Gilead, Daiichi Sankyo, Pierre-Fabre; Michelino De Laurentis (MdL) consultation for astrazeneca, amgen, celgene, daiichi sankyo, EIsai, Eli lilly, Exact science, Gilead, MSD, novartis, pfizer, pierre fabre, roche, seagen; Michela Palleschi (MP) advisory for Novartis and Lilly; Ugo de Giorgi (UdG) advisory Merck, BMS, Janssen, astellas, sanofi, bayer, pfizer, ipsen, novartis, ; grants: astrazeneca, sanofi, roche; Enrico Cortesi (EC) honoraria from MSD and astellas, advisory role for astellas, bayer; research found from merck; Agnese Fabbri (AF) advisory and speaker for lilly, pfizer, roche, novartis, gilead; Alessandra Fabi (AF) advisory board roche, pfizer, novartis, gilead, sophos, Seagen, Astrazeneca, lilly, pierre Fabre, exact science; Ida Paris (IP) fee for Novartis, Gentili, Italfarmaco, Genetic, advisory role for Gilead, AstraZeneca, Lilly, Pfizer, Seagen; Armando Orlandi (AO) fee speaker and advisory: amgen, lilly, pfizer, novartis, daiichi sankyo, gilead; Giuseppe Curigliano (GC) has/had a consultant/advisory role for Roche-Genentech, MSD, Pfizer, BMS, Amgen, Novartis, Pierre Fabre, Gilead, Eli-Lilly, Seagen, Exact Science; Carmen Criscitiello (CC) had consultancy/advisory role/speaker bureau Pfizer Roche msd Novartis Lilly seagen gilead Daiichi-Sankyo; Giuliana D’Auria (GdA) advisory role for amgen, pfizer, lilly, novartis, eisai; Patrizia Vici (PV) advisory role for Pfizer, lilly, eisai, Novartis; Alessio Cirillo (AC) speaker for Novartis, MSD; Daniele Santini (DS) advisory role for Angen, Janssen, Astellas, Bayer, Servier, Novartis, MSD. Merck, Pfizer, Ipsen; Paolo Marchetti (PM) has/had a consultant/advisory role for BMS, Roche, Genentech, MSD, Novartis, Amgen, Merck Serono, Pierre-Fabre, and Incyte. Andrea Botticelli (AB) has/had a consultant/advisory role for Roche-Genentech, MSD, Pfizer, BMS, Amgen, Novartis, Pierre Fabre, Gilead, Eli-Lilly, and Seagen. Competing interests: Maurizio Simmaco (MS), Paolo Marchetti, and Robert Preissner (RP) are members of the Advisory Board of Drug-PIN AG (software expressly cited in the text). The Drug-PIN AG is the holder of the patent PCT/IB2019/052310. The remaining authors declare no competing interests.
